Does menopause shift androgen availability toward adrenal precursors and peripheral conversion?

The transition through menopause, typically occurring around age 51, marks a profound shift in systemic endocrinology. As ovarian function declines and direct ovarian estrogen secretion ceases, the body undergoes a metabolic reorganization to maintain androgen and estrogen homeostasis.

Postmenopausal endocrine shift

• Transition of hormone sources: With the decline in direct ovarian output, the circulating pool of active sex steroids becomes highly dependent on adrenal-derived precursors rather than direct ovarian glandular secretion.
• Continued ovarian activity: Although the postmenopausal ovary continues to secrete some testosterone and androstenedione during the first decade following menopause, the broader androgenic environment is predominantly sustained by the peripheral conversion of adrenal precursors.

Mechanistic pathways of intracrinology

• Adrenal precursors: Dehydroepiandrosterone (DHEA) and its sulfate form (DHEAS), synthesized by the adrenal glands, serve as the primary upstream substrates for local sex steroid synthesis in peripheral organs.
• Local enzymatic conversion: Peripheral target tissues—including adipose tissue, skin, breast, endometrium, and bone—express specific steroidogenic enzymes to convert these precursors. Key enzymes such as steroid sulfatase (STS), 3β-hydroxysteroid dehydrogenase (3β-HSD), and 17β-hydroxysteroid dehydrogenase (17β-HSD) convert DHEA/DHEAS into active androgens (testosterone and dihydrotestosterone) and estrogens (estrone and estradiol).
• Intracrine action: This localized synthesis, or intracrinology, allows individual target tissues to regulate their own physiological hormone exposure locally, bypassing the systemic circulation and preventing active hormone spillover.

Bottom line

• Following menopause, androgen availability shifts from direct ovarian secretion to a localized intracrine system where peripheral tissues convert adrenal precursors (DHEA/DHEAS) into active hormones using tissue-specific enzymes like STS, 3β-HSD, and 17β-HSD.